The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

N. Hunter; Heather A. Parsons; Leslie Cope; J. V. Canzoniero; Fabio C.P. Navarro; Sherif El-Refai; Jesus D. Anampa; Joseph A. Sparano; Mothaffar F. Rimawi; A. Storniolo; Candace Mainor; Rita Nanda; A. DeMichele; Gaorav P. Gupta; E Stringer-Reasor; F. Lynce; Erin F. Cobain; Shannon Puhalla; R. C. Jankowitz; Brent N. Rexer; I. Mayer; E. Shelley Hwang; Kimberly Blackwell; Walid El Ayass; Young Lee; Carol Tweed; Mary Wilkinson; Angela Pennisi; Bonnie Sun; Pamela A. Wright; Julie R. Gralow; Richard Chen; S. M. Boyle; Vered Stearns; Antonio C. Wolff; Ben Ho Park

doi:10.1200/jco-25-02934

Key Points

To evaluate the efficacy of ctDNA in distinguishing patient outcomes after neoadjuvant therapy in breast cancer.
Analyzed circulating tumor DNA (ctDNA) samples from HER2-positive breast cancer and triple-negative breast cancer (TNBC) patients.
Evaluated prognostic capabilities of ctDNA post-neoadjuvant therapy (NAT).
Identified correlation between ctDNA levels and patient outcomes.
ctDNA did not effectively differentiate between pathological complete response (pCR) and non-pCR cases.
Significantly improved prognostic stratification provided insights into patient outcomes.
Findings support the use of ctDNA in guiding treatment decisions for better patient management.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational study evaluates ctDNA's ability to stratify breast cancer outcomes, suggesting new treatment strategies.

Abstract

In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hunter et al. (2026) studied this question.

synapsesocial.com/papers/69b3abe702a1e69014ccd27a https://doi.org/10.1200/jco-25-02934

View at Publisher

Ask AI

Bookmark

Share

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading